Supplementary Files
Keywords
SARS-CoV-2
Breast neoplasm
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To evaluate the outcome of patients diagnosed with COVID-19, who started treatment for breast cancer between 03/18/20 to 07/31/21, in Northern Tocantins. Methods: The studied group was composed by patients diagnosed with COVID 19 and in treatment for breast cancer, regardless of the stage of treatment. This is a retrospective and descriptive study that took place between March 2020 and July 2021. The patients were questioned about the clinical course after being infected with SARS-CoV-2 and we evaluated the outcomes in this group of patients and correlated them with the stage of oncological treatment. Results: We observed that patients with COVID-19 in hormone therapy did not require hospitalization, while 50% of patients undergoing chemotherapy required hospitalization, however, none of the hospitalized women needed to be transferred to an ICU. Conclusion: Therefore we can conclude that the stage of cancer treatment interfered with morbidity, but did not alter the mortality of these women.
References
ARBEL R, et al. Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge. The New England Journal of Medicine, 2022; 387: 790-798.
BRAY F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin., 2018; 68(6): 394-424.
CENTERS FOR DISEASE CONTROL AND PREVENTION - CDC. Gestão de Pacientes confirmado 2019-NCOV. 2022.
CHLEBOWSKI ZC, et al. Ethnicity and Breast Cancer: Factors Infl uencing. Differences in Incidence and Outcome Rowan T. Journal of the National Cancer Institute, 2005; 97: 439.
COHEN P e GEBO K. COVID-19: Evaluation of adults with acute illness in the outpatient setting. 2022. Disponível em: https://www.uptodate.com/contents/covid-19-evaluation-of-adults-with-acute-illness-in-the-outpatient-setting.
COHEN P e GEBO K. COVID-19: Management of adults with acute illness in the outpatient setting. 2022. Disponível em: https://www.uptodate.com/contents/covid-19-management-of-adults-with-acute-illness-in-the-outpatient-setting.
COLLABORATIVE COVID SURG. Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study. The Lancet, 2020; 396(10243): 27-38.
ELLIOTT JH, et al. Living systematic reviews: an emerging opportunity to narrow the evidence-practice gap. PLOS Medicine, 2014; 11(2): e1001603.
ESTADO DO TOCANTINS. Portaria n°188, de 03 de fevereiro de 2020. Plano de Contigência da Epidemia pelo 2019-nCoV. Assistência Hospitalar aos pacientes com Covid 19. Assistência Hospitalar pelo Hospital de Referência HRA. Palmas, TO: Secretaria de Saúde do Estado do Tocantins, 2020.
GOVERNO DO ESTADO DO TOCANTINS. Macrorregiões de Saúde do Estado do Tocantins. Secretaria de Saúde do Estado do Tocantins, 2018.
HOPE ACA. A simplified Monte Carlo significance teste procedure. Journal of the Royal Society Series B. 1968; 30: 582-598.
IBGE. População no último censo. 2020. Disponível em: https://www.ibge.gov.br/estatisticas/sociais/populacao.html.
JORDAN ER, et al. Covid-19: risk factors for severe disease and death. The BMJ, 2020; 368: 1198.
LI Q, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus – infected pneumonia. The New England Journal of Medicine, 2020; 382: 1199-1207.
MA J, et al. Clinical characteristics and prognosis in cancer patients with COVID-19: a single center’s retrospective study [letter]. Journal of Infection, 2020.
MARÇAL RT e VAZ CT. Tratamento do câncer de mama em tempos de COVID- 19: uma revisão integrativa. Research, Society and Development, 2022; 11(10): e252111032915.
MCHUGH ML. The Chi-square test of independence. Biochemia Medica, 2013; 3(2): 143-149.
MINISTÉRIO DA SAÚDE (Brasil). Boletim epidemiológico 05: Doença pelo coronavírus 2019. Secretária de vigilância em saúde, 2020.
MINISTÉRIO DA SAÚDE. Controle dos cânceres do colo do útero e da mama. Ministério da saúde, Secretaria de Atenção à Saúde, Departamento de Atenção Básica. 2013.
NGS. Solução NGS aprimorada e de alto rendimento. 2020.
OLIVEIRA MEC, et al. Atraso na primeira consulta após percepção dos sinais/sintomas de câncer de mama. Revista Família, Ciclos de Vida e Saúde no Contexto Social, 2020; 8(4): 819-826.
ORAN DP e TOPOL EJ. The Proportion of SARS-CoV-2 Infections That Are Asymptomatic. A Systematic Review. Annals of Internal Medicine, 2021; 174(5): 655-662.
PAULINELLI RR, et al. A situação do cancer de mama em Goiás, no Brasil e no mundo: tendências atuais para a incidência e a mortalidade. Revista Brasileira de Saúde Materno Infantil, 2003; 3(1): 17-24.
R CORE TEAM (2021). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna. 2021.
ROSSI FH. Tromboembolismo venoso em pacientes COVID-19. Venous thromboembolism in COVID-19 patients. Jornal Vascular Brasileiro, 2020; 1.
SANTOS DE, et al. Efeito da radioterapia na função pulmonar e na fadiga de mulheres em tratamento para o câncer de mama. Fisioterapia e pesquisa, 2013; 20(1): 50-55.
SECRETARIA DE ESTADO DE SAÚDE. Comissão Intergestores Bipartite/CIB-TO. Resolução N°. 143, de 19 de julho de 2018.
STRABELLI TMV e UIP DE. COVID-19 e o Coração. Arq Bras Cardiol., 2020; 114(4): 598–600.
TABÁR L, et al. The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening. Cancer, 2019; 125: 515.
TONG JY, et al. A prevalência de disfunção olfativa e gustativa em pacientes com COVID-19: uma revisão sistemática e metanálise. Cirurgia de Otorrinolaringol Cabeça Pescoço, 2020; 163: 3.
WORLD HEALTH ORGANIZATION (WHO). Câncer de mama. 2022.
WORD HEALTH ORGANIZATION (WHO). Câncer de mama agora forma mais comum de câncer: OMS tomando medidas. OMS tomando medidas. 2021.